Inflammation among kidney transplant donors with and without HIV: Multicenter HOPE in Action Consortium
- PMID: 40653253
- PMCID: PMC12319627
- DOI: 10.1016/j.clim.2025.110563
Inflammation among kidney transplant donors with and without HIV: Multicenter HOPE in Action Consortium
Abstract
Kidney transplantation from donors with HIV has recently become standard clinical practice, but the plasma inflammatory profile is not well characterized. Thirty-two cytokines and chemokines were evaluated among donors with HIV (n = 63) and without HIV (n = 41). Wilcoxon rank sum test was used to compare cytokines between groups. Donors with and without HIV were generally similar in terms of characteristics, except those with HIV had a non-significantly lower kidney donor profile index, reflecting better graft survival, creatinine, and body mass index. Most cytokine and chemokine levels were similar between groups. However, median IL-8 levels were higher (p < 0.0015) in donors without HIV (32.6 pg/mL, IQR = 13.8-394.9) compared to donors with HIV (15.1 pg/mL, IQR = 8.4-35.5). There were no significant correlations between cytokine and chemokine concentrations and CD4 counts or HIV viral load. In summary, inflammatory profiles were similar or lower among donors with HIV compared to donors without HIV supporting the safety of this emerging kidney transplantation practice.
Keywords: Chemokines; Cytokines; HIV; HOPE Act; Inflammation; Kidney; Organ donation; Organ transplantation; Transplant.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest JH received research grants from Pfizer, Janssen, Ferring, Scynexis, AstraZeneca, and The Antibiotic Resistance Leadership Group (ARLG). Advisory Board at Pfizer, AstraZeneca, and Innoviva. Honoraria payments from ARLG. SM is PI on NIH sponsored Thinker next and CCR5 study and PI on OKRA and Prospera study. DLS reports payments from AstraZeneca, CareDx, Moderna Therapeutics, Medscape, Novavax, Regeneron, Springer Publishing, Hansa, Roche, Sanofi, WebMD and ASN, outside the submitted work. CMD receives payments from Gilead Sciences for serving on a grant review committee and Gilead donates drugs to two trials on which CMD is an investigator also outside the submitted work. All other authors report no relevant conflicts.
References
-
- Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005. May 23;165(10):1179–84. doi: 10.1001/archinte.165.10.1179. Erratum in: Arch Intern Med. 2005 Nov 28;165(21):2541. - DOI - PubMed
-
- Fritz AR, Howell J, Wolfe CR, Noreen SM, Klassen DK. Estimated Median Waiting Time for Organ Procurement and Transplantation Network Human Immunodeficiency Virus Organ Policy Equity Act Variance Kidney Candidates: A Propensity Score Matched Analysis. Transpl Infect Dis. 2025. Jan-Feb;27(1):e14411. doi: 10.1111/tid.14411. Epub 2024 Nov 27. - DOI - PubMed
-
- Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010. Nov 18;363(21):2004–14. doi: 10.1056/NEJMoa1001197. Erratum in: N Engl J Med. 2011 Mar 17;364(11):1082. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials